Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 25Sarcoma 21Lymphoid 8Genitourinary 7Gastrointestinal 6Other hematologic neoplasm 5Gynecologic 5Other solid neoplasm 4Myeloid 3Thoracic 2Dermatologic 2Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 378Pituitary Neoplasms 159Multiple Endocrine Neoplasia Type 1 150Thyroid Cancer, Papillary 122Pheochromocytoma 107Carcinoma, Neuroendocrine 93Thyroid Neoplasms 74Paraganglioma 68Carcinoid Tumor 66Neoplasms 54Thyroid Carcinoma, Anaplastic 50Adrenocortical Carcinoma 47Adrenal Gland Neoplasms 46Neoplasm Metastasis 40Insulinoma 39Pancreatic Neoplasms 36Gastro-enteropancreatic neuroendocrine tumor 36Adenoma, Islet Cell 36Carcinoma, Medullary 29Neuroblastoma 28Adenocarcinoma, Follicular 28Hyperaldosteronism 25Prostatic Neoplasms 24Lung Neoplasms 24Obesity 23Brain Neoplasms 22Pituitary Diseases 21Differentiated Thyroid Cancer 20Cushing Syndrome 20Sarcoma 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Familial ependymoma × Endocrine × Clear all
NCT00049023 2016-06-21

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

University of Iowa

Phase 1 Completed
27 enrolled
CNSEndocrineSarcoma

Familial ependymoma, Insulinoma, Adenoma, Islet Cell, Medulloblastoma, Neuroblastoma, Pheochromocytoma, Sarcoma, Gastrinoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡